- Home
- RVMD vs RGEN Comparison
RVMD vs RGEN Comparison
Compare RVMD & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVMD
- RGEN
- Stock Information
- Founded
- RVMD 2014
- RGEN 1981
- Country
- RVMD United States
- RGEN United States
- Employees
- RVMD N/A
- RGEN N/A
- Industry
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- RGEN Medical/Dental Instruments
- Sector
- RVMD Health Care
- RGEN Health Care
- Exchange
- RVMD Nasdaq
- RGEN Nasdaq
- Market Cap
- RVMD 7.4B
- RGEN 8.0B
- IPO Year
- RVMD 2020
- RGEN N/A
- Fundamental
- Price
- RVMD $39.40
- RGEN $118.07
- Analyst Decision
- RVMD Strong Buy
- RGEN Buy
- Analyst Count
- RVMD 12
- RGEN 12
- Target Price
- RVMD $68.67
- RGEN $172.67
- AVG Volume (30 Days)
- RVMD 2.0M
- RGEN 791.0K
- Earning Date
- RVMD 05-07-2025
- RGEN 04-29-2025
- Dividend Yield
- RVMD N/A
- RGEN N/A
- EPS Growth
- RVMD N/A
- RGEN N/A
- EPS
- RVMD N/A
- RGEN N/A
- Revenue
- RVMD N/A
- RGEN $650,429,000.00
- Revenue This Year
- RVMD N/A
- RGEN $13.93
- Revenue Next Year
- RVMD $241.39
- RGEN $14.35
- P/E Ratio
- RVMD N/A
- RGEN N/A
- Revenue Growth
- RVMD N/A
- RGEN 4.88
- 52 Week Low
- RVMD $29.17
- RGEN $102.97
- 52 Week High
- RVMD $62.40
- RGEN $182.52
- Technical
- Relative Strength Index (RSI)
- RVMD 51.81
- RGEN 39.80
- Support Level
- RVMD $36.53
- RGEN $120.55
- Resistance Level
- RVMD $40.00
- RGEN $123.71
- Average True Range (ATR)
- RVMD 1.80
- RGEN 4.63
- MACD
- RVMD -0.21
- RGEN -0.58
- Stochastic Oscillator
- RVMD 47.28
- RGEN 7.59
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
About RGEN Repligen Corporation
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.